Inventiva announces a new Director of the Board of Directors

Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announces that, effective on November 9th, 2022, Inventiva’s board of directors coopted Dr. Lucy Lu as the Director of its Board of Directors in lieu of Sofinnova Partners.

The nomination of Dr. Lucy Lu will be submitted for ratification by the shareholders during the next general shareholders meeting.

Dr. Lucy Lu has been Sofinnova Partners representative at Inventiva’s Board of Directors since January 4th, 2020. Dr. Lu has over 20 years of extensive experience in the biotechnology and healthcare industries as an investment banker, financial analyst and executive. Dr. Lu is the Chief Operations Officer at Innovative Cellular Therapeutics and prior to this role she served as President and CEO of Avenue Therapeutics. Dr. Lu also worked as a senior biotechnology analyst for Citigroup Inc. and holds an M.D. degree from the New York University School of Medicine.

Frederic Cren, Chairman, CEO and co-founder of Inventiva, commented: “We are pleased to nominate Dr. Lu in the role of Director of Inventiva’s Board of Directors. Dr. Lu has been working with the Board for almost 3 years, and her global knowledge of the industry is a great asset for the Company as we are continuing to develop lanifibranor and have signed a first licensing agreement for the development and commercialisation of lanifibranor in Greater China. I want to thank Dr. Lu for her continued participation on the Board. On behalf of the Board of Directors, I also want to thank Sofinnova Partners for their contribution to Inventiva over the past 3 years.”

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH, MPS and other diseases with significant unmet medical need. The company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.
Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of adult patients with NASH and obtained both FDA Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential.

further development. Inventiva is also in the process of selecting an oncology development candidate for its Hippo signaling pathway program.
The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com

Contacts

Pascaline Clerc
VP of Global External Affairs
media@inventivapharma.com
+1 240 620 9175

Brunswick Group
Laurence Frost /
Tristan Roquet Montegon
Aude Lepreux
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513 1284